Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1965 1
1967 1
1970 6
1971 2
1972 1
1973 5
1974 6
1975 2
1976 2
1977 4
1978 6
1979 5
1980 5
1981 3
1982 4
1983 2
1984 3
1985 3
1986 7
1987 3
1988 1
1990 4
1991 3
1992 4
1993 7
1994 6
1995 9
1996 4
1997 7
1998 5
1999 13
2000 7
2001 6
2002 9
2003 9
2004 8
2005 8
2006 3
2008 14
2009 8
2010 9
2011 15
2012 15
2013 15
2014 11
2015 8
2016 4
2017 3
2018 5
2019 4
2020 8
2021 13
2022 11
2023 10
2024 17

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

330 results

Results by year

Filters applied: . Clear all
Page 1
Baricitinib in juvenile idiopathic arthritis: an international, phase 3, randomised, double-blind, placebo-controlled, withdrawal, efficacy, and safety trial.
Ramanan AV, Quartier P, Okamoto N, Foeldvari I, Spindler A, Fingerhutová Š, Antón J, Wang Z, Meszaros G, Araújo J, Liao R, Keller S, Brunner HI, Ruperto N; JUVE-BASIS investigators; Paediatric Rheumatology International Trials Organisation. Ramanan AV, et al. Lancet. 2023 Aug 12;402(10401):555-570. doi: 10.1016/S0140-6736(23)00921-2. Epub 2023 Jul 6. Lancet. 2023. PMID: 37423231 Free article. Clinical Trial.
Is DOPA a neurotransmitter?
Misu Y, Goshima Y, Miyamae T. Misu Y, et al. Among authors: miyamae t. Trends Pharmacol Sci. 2002 Jun;23(6):262-8. doi: 10.1016/s0165-6147(02)02013-8. Trends Pharmacol Sci. 2002. PMID: 12084631 Review.
Juvenile fibromyalgia: Guidance for management.
Yokota S, Kikuchi M, Miyamae T. Yokota S, et al. Among authors: miyamae t. Pediatr Int. 2013 Aug;55(4):403-9. doi: 10.1111/ped.12155. Pediatr Int. 2013. PMID: 23758613 Review.
Arthritis mutilans in juvenile idiopathic arthritis.
Miyamae T, Akatsu M, Ichikawa N, Taniguchi A, Harigai M. Miyamae T, et al. Lancet Rheumatol. 2021 Feb;3(2):e160. doi: 10.1016/S2665-9913(20)30337-4. Epub 2020 Nov 18. Lancet Rheumatol. 2021. PMID: 38279371 No abstract available.
Low remission rates and high incidence of adverse events in a prospective VEXAS syndrome registry.
Kirino Y, Maeda A, Asano T, Migita K, Hidaka Y, Ida H, Kobayashi D, Oda N, Rokutanda R, Fujieda Y, Atsumi T, Kishida D, Kobayashi H, Shiratsuchi M, Shimizu T, Kawakami A, Tanaka K, Tsuji T, Mishima K, Miyamae T, Hasegawa A, Ikeda K, Watanabe T, Yamaguchi Y, Nishikomori R, Ohara O, Nakajima H; Japan VEXAS study group. Kirino Y, et al. Among authors: miyamae t. Rheumatology (Oxford). 2024 Sep 28:keae530. doi: 10.1093/rheumatology/keae530. Online ahead of print. Rheumatology (Oxford). 2024. PMID: 39340799
Anti-nuclear matrix protein 2 antibody-positive inflammatory myopathies represent extensive myositis without dermatomyositis-specific rash.
Ichimura Y, Konishi R, Shobo M, Inoue S, Okune M, Maeda A, Tanaka R, Kubota N, Matsumoto I, Ishii A, Tamaoka A, Shimbo A, Mori M, Morio T, Kishi T, Miyamae T, Tanboon J, Inoue M, Nishino I, Fujimoto M, Nomura T, Okiyama N. Ichimura Y, et al. Among authors: miyamae t. Rheumatology (Oxford). 2022 Mar 2;61(3):1222-1227. doi: 10.1093/rheumatology/keab518. Rheumatology (Oxford). 2022. PMID: 34152410
330 results